Abeona Q1 net loss $31.6M; BLA resubmission expected H2 2024; closed $75M offering

ABEONA THERAPEUTICS INC.

2024-Q1 EPS reported -$1.16

Net loss $31.6M ($1.16/share) vs. $9.1M loss a year ago; cash $62.7M at March 31, up from $52.6M.
Closed $75M underwritten offering on May 7, 2024; cash runway extended into 2026.
FDA CRL in April 2024 cited CMC deficiencies; no efficacy/safety issues; BLA resubmission planned H2 2024.
R&D expense $7.2M (down 10% YoY); G&A expense $7.1M (up 78% YoY).
Entered $50M credit facility in Jan 2024, drew $20M first tranche.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ABEONA THERAPEUTICS INC. reported first quarter of 2024 results: net income Net loss was $31.6 million for the first quarter of 2024, or $1.16 loss per common share, EPS $1.16 loss per common share.

Period: first quarter of 2024
Net income: Net loss was $31.6 million for the first quarter of 2024, or $1.16 loss per common share
EPS: $1.16 loss per common share
Result: reported results

Exact text from the filing

Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2024

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

ABEONA THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-019449

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.